<DOC>
	<DOCNO>NCT01880437</DOCNO>
	<brief_summary>This study ass safety efficacy vismodegib patient relapsed/refractory acute myelogenous leukemia ( AML ) relapsed/refractory high-risk myelodysplastic syndrome ( MDS ) . Patients Cohort 1 receive single-agent vismodegib 150 mg orally daily . In Cohort 2 , patient receive vismodegib 150 mg orally daily combination cytarabine 20 mg subcutaneously 10 day . Anticipated time study treatment disease progression , intolerable toxicity , patient withdrawal consent .</brief_summary>
	<brief_title>A Study Vismodegib Patients With Relapsed/Refractory Acute Myelogenous Leukemia Relapsed Refractory High-Risk Myelodysplastic Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Patients document relapsed refractory AML , except acute promyelocytic leukemia ( APL [ M3 subtype ] ) , relapse refractory highrisk MDS ( highrisk MDS define International Prognostic Scoring System ( IPSS ) Int2 high &gt; /= 10 % blast bone marrow ) Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 Negative serum pregnancy test woman childbearing potential use two form contraception enrol study 7 month patient discontinues study Male patient female partner childbearing potential must agree use latex condom advise female partner use additional method contraception study 2 month last dose vismodegib All nonhematological adverse event prior chemotherapy , surgery , radiotherapy must resolve National Cancer Institute Common Terminology Criteria Adverse Events ( NCI CTCAE ) Grade &lt; /= 2 prior start therapy Adequate hepatic renal function Prior treatment Hh pathway inhibitor Prior therapy treatment malignancy within 14 day Day 1 , exception : Hydroxyurea patient need continue agent maintain white blood cell ( WBC ) count &lt; /= 50,000/mL . Hydroxyurea must discontinue Day 14 study Current evidence active central nervous system ( CNS ) leukemia Any active malignancy ( except nonmelanoma skin cancer carcinoma situ cervix ) Any severe and/or uncontrolled medical condition condition could affect participation study : Unstable angina , symptomatic otherwise uncontrolled arrhythmia require medication ( include stable , lone atrial fibrillation ) , myocardial infarction &lt; /= 6 month study treatment start Any active ( acute chronic ) uncontrolled infection/disorders impair ability evaluate patient patient complete study Pregnant breastfeed woman Patients refuse potentially receive blood product and/or severe hypersensitivity blood product</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>